Drug intelligence / Profile preview

prodiol cannabinoids

Development stage
Preclinical
Lead developer
InMed Pharmaceuticals
Modality
Small Molecules
Administration
Oral, Topical, Ophthalmic
01

Overview

Prodiol cannabinoids refer to a pipeline of rare cannabinoid analogs and bio-identical compounds developed by BayMedica, a subsidiary of InMed Pharmaceuticals. The Prodiol line is centered around cannabidiol (CBD) and its structural derivatives, produced using a proprietary hybrid synthetic biology and chemistry platform. These small molecules are designed to interact with the endocannabinoid system and related pathways, such as TRP channels and G-protein coupled receptors, to address various therapeutic areas including inflammatory diseases and neurological disorders. The "Additional Prodiol cannabinoids" entry in the company's pipeline represents a collection of these derivatives currently in preclinical development.

Brand names
Prodiol
Other names
BayMedica cannabinoids
02

Targets

CNR1 (Cannabinoid receptor 1)TRPA1 (Transient receptor potential cation channel subfamily A member 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)GPR55 (G protein-coupled receptor 55)

Beyond the preview

Go deeper on prodiol cannabinoids.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on prodiol cannabinoids.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call